Morgan Stanley analysts have estimated that Lilly’s GLP-1 pill could bring in as much as $40 billion in annual sales by 2033.

A DAILY weight loss pill, tipped to be cheaper than popular jabs, has helped patients shed nearly two stone in trials. People ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

When Serena Williams told NBC’s “TODAY” show, “I just couldn’t get my weight to where I needed to be at a healthy place and ...

Eli Lilly's GLP-1 pill, orforglipron, shows promising trial results for weight loss and type 2 diabetes. Global regulatory ...

In new Phase III trial data released Tuesday, people taking orforglipron lost substantially more weight than people taking a ...

The 36-mg dose brought the greatest weight loss, 10.5%, while the 12-mg dose group shed 7.8% of their body weight on average.

GLP-1 medications have been known to come with a raft of side effects, including weight loss and drastic changes to users' ...

Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

Novo Nordisk NVO suffered a major setback in July after slashing its 2025 sales and profit outlook, triggering a decline in ...

With around 73 percent of Americans enjoying their daily coffee fix, it’s natural to wonder how your morning cup might ...